Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
2(12%)
Results Posted
13%(1 trials)
Terminated
1(6%)

Phase Distribution

Ph not_applicable
1
6%
Ph phase_2
3
18%
Ph phase_3
1
6%
Ph phase_1
12
71%

Phase Distribution

12

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
12(70.6%)
Phase 2Efficacy & side effects
3(17.6%)
Phase 3Large-scale testing
1(5.9%)
N/ANon-phased studies
1(5.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

17

all time

Status Distribution
Active(4)
Completed(8)
Terminated(3)
Other(2)

Detailed Status

Completed8
unknown2
Not yet recruiting2
Recruiting2
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
2
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 112 (70.6%)
Phase 23 (17.6%)
Phase 31 (5.9%)
N/A1 (5.9%)

Trials by Status

unknown212%
terminated16%
not_yet_recruiting212%
completed847%
recruiting212%
withdrawn212%

Recent Activity

2 active trials
Showing 5 of 17
recruitingphase_1

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752
not_yet_recruitingphase_2

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

NCT06805656
not_yet_recruitingphase_3

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

NCT06749925
withdrawnphase_1

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

NCT05321940
recruitingphase_1

Neoantigen Derived DCs as Cancer Treatment

NCT05767684
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT05809752Phase 1

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Recruiting
NCT06805656Phase 2

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not Yet Recruiting
NCT06749925Phase 3

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Not Yet Recruiting
NCT05321940Phase 1

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Withdrawn
NCT05767684Phase 1

Neoantigen Derived DCs as Cancer Treatment

Recruiting
NCT01946373Phase 1

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Unknown
NCT01197625Phase 1

Vaccine Therapy in Curative Resected Prostate Cancer Patients

Unknown
NCT01808820Phase 1

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Completed
NCT00492947Phase 1

Dendritic Cell Vaccine for Head and Neck Cancer

Withdrawn
NCT02961829Not Applicable

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Completed
NCT00323115Phase 2

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

Completed
NCT00796770Phase 1

Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)

Completed
NCT01902771Phase 1

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

Terminated
NCT01413295Phase 2

Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer

Completed
NCT00402142Phase 1

Dendritic Cell Vaccine in HIV-1 Infection

Completed
NCT00576446Phase 1

Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients

Completed
NCT00700167Phase 1

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

Completed

All 17 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
17